Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9. https://doi.org/10.1182/blood-2003-06-1841.

Article  PubMed  CAS  Google Scholar 

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–16. https://doi.org/10.1056/NEJMoa1214561.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534–44. https://doi.org/10.1111/bjh.15051.

Article  PubMed  CAS  Google Scholar 

Chan EHL, Koh LP, Lee J, De Mel S, Jeyasekharan A, Liu X, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019;8(10):4626–32. https://doi.org/10.1002/cam4.2347.

Article  PubMed  PubMed Central  Google Scholar 

Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018;24(10):2133–8. https://doi.org/10.1016/j.bbmt.2018.06.009.

Article  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. https://doi.org/10.1016/S0140-6736(20)31366-0.

Article  PubMed  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. https://doi.org/10.1056/NEJMoa1804980.

Article  PubMed  CAS  Google Scholar 

Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, et al. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021;5(18):3563–7. https://doi.org/10.1182/bloodadvances.2021004880.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024;38(5):1107–14. https://doi.org/10.1038/s41375-024-02213-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–5. https://doi.org/10.1182/blood-2013-10-535443.

Article  PubMed  CAS  Google Scholar 

Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, et al. Primary mediastinal B-cell lymphoma: a 2021 update on genetics, diagnosis, and novel therapeutics. Clin Lymphoma Myeloma Leuk. 2021;21(11):e865. https://doi.org/10.1016/j.clml.2021.06.012.

Article  PubMed  CAS  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48.

Article  PubMed  PubMed Central  Google Scholar 

Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83. https://doi.org/10.1182/blood-2017-07-740993.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291–9. https://doi.org/10.1200/JCO.19.01389.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141–5. https://doi.org/10.1182/blood.2022019340.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kato K, Nakamura S, Wakana A, Koh Y, Izutsu K. Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study. Int J Clin Oncol. 2024;29(12):1977–83. https://doi.org/10.1007/s10147-024-02627-8.

Article  PubMed  CAS  Google Scholar 

Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol. 2020;214:108382. https://doi.org/10.1016/j.clim.2020.108382.

Article  PubMed  CAS  Google Scholar 

Pérez-Moreno MA, Ciudad-Gutiérrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Martín L, Flores-Moreno S. Combined or sequential treatment with immune checkpoint inhibitors and Car-T cell therapies for the management of haematological malignancies: a systematic review. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241914780.

Article  PubMed  PubMed Central  Google Scholar 

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–56. https://doi.org/10.1038/nbt.4195.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, et al. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024;8(2):453–67. https://doi.org/10.1182/bloodadvances.2023011287.

Article  PubMed  CAS  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/NEJMra1703481.

Article  PubMed  CAS  Google Scholar 

Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Blood. 2018;132(1):4198. https://doi.org/10.1182/blood-2018-99-119502.

Article  Google Scholar 

Zhou Y, Mu W, Wang C, Zhuo Z, Xin Y, Li H. Ray of dawn: anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in lymphoma patients. BMC Cancer. 2023;23(1):1019. https://doi.org/10.1186/s12885-023-11536-4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Galtier J, Mesguich C, Sesques P, Dupont V, Bachy E, Di Blasi R, et al. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry. Hemasphere. 2025;9(2):e70091. https://doi.org/10.1002/hem3.70091.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023;7(16):4528–38. https://doi.org/10.1182/bloodadvances.2023010016.

Article